AKBA Stock Summary and Trading Ideas (Akebia Therapeutics | NASDAQ:AKBA)

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Akebia Therapeutics trades on the NASDAQ stock market under the symbol AKBA.

As of April 19, 2024, AKBA stock price declined to $1.34 with 892,203 million shares trading.

AKBA has a beta of 1.61, meaning it tends to be more sensitive to market movements. AKBA has a correlation of 0.04 to the broad based SPY ETF.

AKBA has a market cap of $280.56 million. This is considered a Small Cap stock.

Last quarter Akebia Therapeutics reported $56 million in Revenue and $.00 earnings per share. This beat revenue expectation by $806,000 and exceeded earnings estimates by $.04.

In the last 3 years, AKBA stock traded as high as $4.33 and as low as $.24.

The top ETF exchange traded funds that AKBA belongs to (by Net Assets): VTI, VXF, FESM, QQQS.

AKBA has outperformed the market in the last year with a return of +96.4%, while the SPY ETF gained +21.8%. However, in the most recent history, AKBA shares have underperformed the stock market with its stock returning -4.3% in the last 3 month period and -11.3% for the last 2 week period, while SPY has returned +4.8% and -3.0%, respectively.

AKBA support price is $1.30 and resistance is $1.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKBA stock will trade within this expected range on the day.